Nuvastatic represents a breakthrough solution in addressing cancer-related fatigue (CRF), a debilitating condition that significantly reduces patients’ quality of life and treatment adherence. Developed through extensive scientific research and supported by clinical trials, Nuvastatic offers a safe, evidence-based botanical drug that restores energy, improves physical endurance, and enhances overall wellbeing in patients undergoing cancer treatment. From a commercial perspective, Nuvastatic addresses a critical unmet medical need in oncology care, opening opportunities in both hospital and retail markets. Its positioning as a scientifically validated herbal-based therapeutic not only differentiates it from conventional supplements but also creates a strong competitive advantage in the growing global market for integrative cancer care solutions.
Supported by a randomized, double-blind, placebo-controlled Phase II clinical trial showing significant improvement in fatigue scores and quality of life in cancer patients undergoing chemotherapy.
Demonstrated minimal and mild side effects (e.g., mild fever, headache, occasional nausea) compared to synthetic drugs, making it safer and better tolerated for vulnerable cancer patients.
Provides both symptomatic relief of fatigue and biological effects (reduces oxidative stress markers and inflammation), addressing the underlying pathophysiology of CRF.
Already supplied to Icon Cancer Centre Hospital Malaysia and expanding to ICON ASEAN, demonstrating real-world clinical acceptance in oncology care settings.
Few effective pharmacological treatments exist for cancer-related fatigue; Nuvastatic has a first-mover advantage in this unmet therapeutic space.